Skip to main content
IMS Events Main banner
Rate ePoster

    Nursing and Allied Health Symposium

    Category: Nursing & Allied Health Symposium

    Expanding Access to Bispecific Antibodies for Multiple Myeloma: A Multidisciplinary Model to Bridge Academic and Community Care

    (NSP-02) Expanding Access to Bispecific Antibodies for Multiple Myeloma: A Multidisciplinary Model to Bridge Academic and Community Care

    Thursday, September 18, 2025
    Introduction: T-cell redirecting BsAbs for MM offer high efficacy but carry early toxicity risks,typically necessitating initial inpatient administration and specialized monitoring during the ramp-up phase.This has limited treatment availability to larger cancer centers and created disparities in access for patients in rural or community settings.To address this gap, our multidisciplinary team launched a structured education and referral program aimed at safely expanding BsAb access beyond academic centers.

    Methods: This initiative included the development of comprehensive educational resources covering mechanisms of action,eligibility, toxicity management,efficacy, and drug sequencing.Training for community based oncology teams was delivered via inperson sessions and virtual telementoring, led by a physician,APP,pharmacist, and nurse navigator.Standardized outpatient workflows were also created,incorporating a wearable monitoring device,home-based care services, and escalation protocols for managing CRS and neurotoxicity.Electronic, real-time surveys were employed to assess knowledge and comfortability with BsABs before and after each educational session.

    Results: Fifty interdisciplinary clinicians participated in pre- and post-training surveys assessing knowledge and confidence related to BsAb therapy.While not all participants answered every question, the data showed consistent improvements across all measured domains.Comfort with managing BsAb-associated toxicities increased from less than half of respondents(47%,14/30)pretraining to nearly all respondents(95%,35/37)posttraining, the most substantial gain.Knowledge of infection monitoring improved from 46% to 90% while the ability to identify neurotoxicity symptoms rose from 66% to 88%.Recognition of appropriate medications for CRS symptoms increased from 67% (33/49) to 92% (45/49)while knowledge of eligibility criteria for prior therapies improved from 32% to 64%.Additionally,Confidence in recognizing fever as the most common CRS symptom increased from 59% to 96%.1/3of respondents felt side effect management,inpatient bed constraints,and staffing limitations were barriers to initiating ramp-up, hough 100% of centers hoped to initiate treatment when possible. All respondents reported satisfaction with the training and indicated they would recommend it to colleagues.

    Conclusions: Despite educational improvements,barriers remain primarily staffing limitations and ongoing needs for team-wide education.Formal care pathways were established to support transitioning patients back to local providers following initial dosing,ensuring continuity and safety across care settings.This model of collaborative education,referral,and shared management has demonstrated early success in increasing provider readiness and creating safer,more equitable access to BsAb therapies for MM.Ongoing expansion and refinement aim to further close the access gap and ensure community teams are equipped to deliver high-quality care with appropriate academic support.